Expert Interviews

Dr. Zeitouni compares immune-mediated adverse event rates across checkpoint inhibitor agents in advanced CSCC.

Dr. Binod Dhakal leads a discussion on patient selection for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM), focusing on how these therapies fit within an increasingly complex treatment landscape.

The panel reviews a 58-year-old patient with HR-positive, HER2-negative metastatic breast cancer progressing after endocrine therapy plus CDK4/6 inhibitor treatment. The patient has hepatic and bone metastases with radiographic and symptomatic progression, ECOG performance status 1, controlled hypertension, and mild dry eye syndrome. She prioritizes maintaining professional activity and independence.

Recurrent facial squamous cell cancer with CLL challenges surgery and radiation; experts weigh immunotherapy, cemiplimab data, and patient goals.

Amer Zeidan, MBBS, MD, discusses whether the expanding lower-intensity arsenal has narrowed the definition of a patient with AML who is unfit.

Orca-T is a “big advance” that must be studied further among patients with acute leukemias and myelodysplastic syndromes.

Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

This segment focuses on assessing bleeding and variceal risk before initiating anti-VEGF therapy with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee review the key efficacy and safety findings from the phase 3 MonumenTAL-3 study in relapsed/refractory multiple myeloma (RRMM).

The panel discusses long-term survival and quality of life with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee discuss the clinical rationale behind the phase 3 MonumenTAL-3 study and its role in confirming the benefit-risk profile of talquetamab in relapsed/refractory multiple myeloma (RRMM).

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Jonathan Lee, MD, MSc, and Chinmay Jani, MD, have a candid conversation about what medical training actually feels like.

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.

Sivraj Muralikrishnan, MD, analyzed HARMONi-6 safety findings for ivonescimab in NSCLC, addressing VEGF-related toxicities and global generalizability.

Education and reinforcement may improve luspatercept dose titration and persistence in community practice.

Experts weigh CML PCR milestones, urging context over rigid cutoffs when switching TKIs—and keeping treatment‑free remission goals in sight.

Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed sequencing options like luspatercept after ESA failure in RS-negative lower-risk MDS.

Dr. Lipsky addresses the framework for interpreting real-world data and cross-trial comparisons in the absence of head-to-head trials.

Clinicians weigh earlier T‑DXd use in breast cancer by preventing nausea, managing fatigue via dose reductions, and closely monitoring ILD risk in curative settings.

Experts discuss evolving care for HER2-positive metastatic breast cancer brain metastases, highlighting CNS-active drugs, earlier MRI screening, and smarter treatment decisions.

Dr. Lipsky outlines MRD testing utility across the three major treatment approaches.

Imetelstat may be considered as a frontline option for patients with a high transfusion burden, said Amer Zeidan, MBBS, MD.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss using CELMoDs to debulk tumor or restore T-cell fitness between T-cell–redirecting therapies in relapsed/refractory multiple myeloma.

Dr. Binod Dhakal leads a discussion on the increasingly complex treatment landscape of relapsed/refractory multiple myeloma (RRMM), focusing on how clinicians navigate sequencing decisions among BCMA-directed therapies, including CAR T-cell therapy and bispecific antibodies.

The TOP trial, a phase three study focused exclusively on TP53-mutant EGFR-mutant non-small cell lung cancer, validated the FLAURA2 findings in this high-risk subset, showing a striking PFS benefit of 34.0 versus 15.6 months (HR 0.44) for osimertinib plus chemotherapy over monotherapy, with a favorable duration of response of 32.7 versus 15.9 months, though overall survival data remain immature.

Dr. Park addresses management of low-grade immune-related adverse events (irAEs), the most common toxicities encountered with checkpoint inhibitors, including dermatitis, pruritus, and GI symptoms.